Brind.

Marc Grasso was appointed CFO of Kyverna Therapeutics, following his previous roles at Kura Oncology, Morgan Stanley, and UBS.

1 report, 0 independent Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Marc Grasso was appointed CFO of Kyverna Therapeutics, following his previous roles at Kura Oncology, Morgan Stanley, and UBS.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet